Thymogen

Immune

Also known as: Thymogen, Glutamyl-Tryptophan, L-Glu-L-Trp, gamma-glutamyl-tryptophan

Tier 4, Documented harm or no usable evidence

Either documented serious adverse events in humans, or effectively no retrievable evidence base. Dosing figures circulating for these compounds have no scientific foundation.

Half-life

Not established

No rigorous published human pharmacokinetics. Thymogen is the synthetic dipeptide Glu-Trp derived from Thymalin; part of the same Khavinson lineage. PubChem entry (CID 100094) corresponds to glutamyl-tryptophan.

Dosing

No established dose

No FDA/EMA-standardized dosing. Russian intranasal/IM formulations exist but are not verifiable against a regulated label at approved-host sources.

Regulatory status

Not approved by FDA or EMA. Used clinically in Russia/former USSR as an immunomodulator; no major-regulator approval for a defined indication.

Evidence base

mixed · confidence: unknown

In-vitro/animal work and Russian clinical reports (Khavinson lineage); little independent Western replication; no modern human PK.

Safety

No boxed warning (unapproved). No controlled safety data at Western regulatory standards.

Sources